Pharmicell Co (XKRX:005690) Other Long-Term Liabilities : ₩313 Mil (As of Mar. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Other Long-Term Liabilities?

Pharmicell Co's other long-term liabilities for the quarter that ended in Mar. 2024 was ₩313 Mil.

Pharmicell Co's quarterly other long-term liabilities increased from Sep. 2023 (₩302 Mil) to Dec. 2023 (₩344 Mil) but then declined from Dec. 2023 (₩344 Mil) to Mar. 2024 (₩313 Mil).

Pharmicell Co's annual other long-term liabilities declined from Dec. 2021 (₩471 Mil) to Dec. 2022 (₩373 Mil) and declined from Dec. 2022 (₩373 Mil) to Dec. 2023 (₩344 Mil).

Pharmicell Co Other Long-Term Liabilities Historical Data

The historical data trend for Pharmicell Co's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Other Long-Term Liabilities Chart

Pharmicell Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Pharmicell Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Pharmicell Co Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Pharmicell Co Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmicell Co (XKRX:005690) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines